Teva Pharmaceutical Industries Ltd. Press Releases https://ir.tevapharm.com/generated by Q4Tue, 07 Apr 2026 21:06:37 -0400Copyright Q4 Inc. All rights reserved.Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)8a5067d9-0ad3-4c75-8964-08ac64fd6608https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Gains-Biosimilar-Momentum-with-U-S--FDA-Approval-of-PONLIMSI-denosumab-adet-and-Dual-Filing-Acceptance-for-Biosimilar-Candidate-to-Xolair-omalizumab/default.aspxMon, 30 Mar 2026 08:00:00 -0400Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026a5689ad6-e927-49b5-8890-88cb37d0da98https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Host-Conference-Call-to-Discuss-First-Quarter-2026-Financial-Results-at-8-a-m--ET-on-April-29-2026/default.aspxThu, 19 Mar 2026 16:30:00 -0400Teva Releases Q1 2026 Aide Memoire42773011-a6c3-4e53-a3d8-e30e38d9ed03https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Releases-Q1-2026-Aide-Memoire/default.aspxThu, 19 Mar 2026 16:30:00 -0400Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug763c2a97-37b7-4956-b9dc-32e3f49530b1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Blackstone-Life-Sciences-Announce-400-Million-Strategic-Growth-Capital-Agreement-to-Advance-duvakitug/default.aspxTue, 03 Mar 2026 17:00:00 -0500Teva to Present at the Upcoming Investor Conferences in Marchd084ceaf-ea97-44cf-b46b-da8f0ef7bdd4https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Present-at-the-Upcoming-Investor-Conferences-in-March/default.aspxTue, 24 Feb 2026 16:30:00 -0500U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults052219a7-247a-4813-a7cb-d642b2fd4973https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-FDA-Accepts-Tevas-New-Drug-Application-NDA-for-Olanzapine-Extended-Release-Injectable-Suspension-TEV-749-for-the-Once-Monthly-Treatment-of-Schizophrenia-in-Adults/default.aspxFri, 20 Feb 2026 14:43:00 -0500Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s diseasefb64e2dd-dfb8-4bd3-9312-121afd5ba9d2https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Sanofis-duvakitug-phase-2b-maintenance-data-demonstrated-clinically-meaningful-durable-efficacy-in-ulcerative-colitis-and-Crohns-disease/default.aspxTue, 17 Feb 2026 06:00:00 -0500Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potentialfd01a983-5aac-490d-92ce-30a195cab229https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Innovative-Portfolio-and-Consistent-Execution-of-Pivot-to-Growth-Strategy-Deliver-Third-Consecutive-Year-of-Growth-Pipeline-Positioned-to-Unlock-Significant-Value-Potential/default.aspxWed, 28 Jan 2026 07:00:00 -0500Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’f017b1fb-07b7-42a1-a511-9399fc209204https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Will-Forte-Teams-Up-with-Teva-to-Get-Real-About-Huntingtons-Disease-with-Honestly-HD/default.aspxTue, 27 Jan 2026 08:00:00 -0500AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicineadd87aa6-656e-4341-8c1e-461d051ddbb0https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/AJOVY-fremanezumab-vfrm-Significantly-Reduced-Monthly-Migraine-and-Headache-Days-in-Children-and-Adolescents-with-Episodic-Migraine-Compared-to-Placebo-in-the-SPACE-Trial-Results-Published-in-New-England-Journal-of-Medicine/default.aspxWed, 14 Jan 2026 17:02:00 -0500